Team Veye September 22, 2026

Genetic Signatures and Microba Agree to Commercial Terms for $51 Million Scrip Merger

Get your Free Report on Top 5 ASX stocks for 2025

Australian molecular diagnostics developer Genetic Signatures Limited (ASX: GSS) and microbiome specialist Microba Life Sciences Limited (ASX: MAP) has agreed to commercial terms on 22 September 2026 for an all scrip merger to create an enlarged ASX listed diagnostics group.

The transaction is structured as a court approved Scheme of Arrangement where GSS will acquire 100% of Microba’s issued shares and options. Microba shareholders will receive 0.654 new GSS shares per Microba share held, issuing approximately 469 million new shares.

Microba securityholders will own roughly 67% of the merged group upon completion while existing GSS investors will retain approximately 33%. The proposal remains subject to definitive contract execution, shareholder approvals and standard regulatory and court sign-offs.

Leadership stated that pairing GSS’s targeted pathogen detection platform with Microba’s metagenomic profiling will establish a leading franchise in gastrointestinal and infectious disease testing. The combined entity aims to cross sell diagnostic portfolios by leveraging established international pathology relationships including partnerships with Sonic Healthcare and SYNLAB.

Management also expects the consolidation to generate $2.5 million to $3.0 million in annual gross cost synergies by eliminating duplicated public company and administrative expenses.

The combined group reported an aggregate FY2026 revenue of approximately $29.6 million and holds around $30 million in cash and term deposits as of 30 June 2026 which provides a financial runway to accelerate clinical commercialization across Europe, the US and Australia. An equally balanced six member board which is split between both entities will oversee pipeline integration and broader diagnostic distribution.

The merged company will continue trading under the GSS ticker on the ASX, reflecting an indicative combined equity valuation of approximately $51 million.

(Source: Company Announcements)

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

Name

Email address

Phone

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.